Dima is the co-founder and managing partner of 4BIO Capital. He has led the 4BIO effort to promote the advanced therapies field as an early-stage investor and adviser to newly forming companies.

Before co-founding 4BIO, he served as a Doctoral Fellow in neurobiology at the Max Planck Institute for Brain Research and a Research Fellow in optogenetics and gene therapy for CNS disease at the University College London Institute of Neurology.

Dima has twelve peer-reviewed publications in high-impact journals, including Cell, Nature Structural & Molecular Biology, Nature Reviews Drug Discovery and others.

He leads the technical team at 4BIO and has served on the boards of several biotech companies, including RetroSense Therapeutics (an optogenetics startup acquired by Allergan for $550m in September 2016), RedPin Therapeutics (acquired by Kriya Therapeutics), Vespula Therapeutics, Hornet Therapeutics, Ray Therapeutics, Trogenix and Araris Biotech.

Dima holds a PhD (summa cum laude) in Neurochemistry from the Max Planck Institute for Brain Research and the Lomonosov Moscow State University, a MSc in Experimental and Translational Therapeutics from the University of Oxford (with distinction), and a MSc in biochemistry and medical biochemistry from the Lomonosov Moscow State University.

He is a Kauffman Fellow (Class 26), serves as an Assistant Professor of Medicine (Adjunct) at Yale University School of Medicine and is a Fellow of the Royal Society of Medicine (2022) and of the Royal Society of Biology (2021).